 Connection
Peter Crooks to Mice
This is a "connection" page, showing publications Peter Crooks has written about Mice.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.478 |
|
|
|
-
Albayati ZAF, Janganati V, Chen Z, Ponder J, Breen PJ, Jordan CT, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. Bioorg Med Chem. 2017 02 01; 25(3):1235-1241.
Score: 0.067
-
Crooks PA, Zheng G, Vartak AP, Culver JP, Zheng F, Horton DB, Dwoskin LP. Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011; 11(9):1103-27.
Score: 0.044
-
Worthen DR, Bence AK, Stables JP, Crooks PA. In vivo evaluation of diaminodiphenyls: anticonvulsant agents with minimal acute neurotoxicity. Bioorg Med Chem Lett. 2009 Sep 01; 19(17):5012-5.
Score: 0.040
-
Gali-Muhtasib HU, Abou Kheir WG, Kheir LA, Darwiche N, Crooks PA. Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes. Anticancer Drugs. 2004 Apr; 15(4):389-99.
Score: 0.028
-
Liu X, Gao Z, Fu Q, Song L, Zhang P, Zhang X, Hendrickson H, Crooks PA, Zhou D, Zheng G. Deuteration of the farnesyl terminal methyl groups of d-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production. Bioorg Med Chem. 2020 06 01; 28(11):115498.
Score: 0.021
-
Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with ?9-Tetrahydrocannabinol and JWH-018. J Pharmacol Exp Ther. 2019 05; 369(2):259-269.
Score: 0.020
-
Wang R, Bhat-Nakshatri P, Padua MB, Prasad MS, Anjanappa M, Jacobson M, Finnearty C, Sefcsik V, McElyea K, Redmond R, Sandusky G, Penthala N, Crooks PA, Liu J, Zimmers T, Nakshatri H. Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. Mol Cancer Ther. 2017 Dec; 16(12):2747-2758.
Score: 0.018
-
Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov; 125(Pt B):161-177.
Score: 0.018
-
Mendonca MS, Turchan WT, Alpuche ME, Watson CN, Estabrook NC, Chin-Sinex H, Shapiro JB, Imasuen-Williams IE, Rangel G, Gilley DP, Huda N, Crooks PA, Shapiro RH. DMAPT inhibits NF-?B activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 11; 112:318-326.
Score: 0.017
-
Smith CA, Mont S, Traver G, Sekhar KR, Crooks PA, Freeman ML. Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy. Oncotarget. 2016 Nov 22; 7(47):77926-77936.
Score: 0.017
-
Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, Pratt MA. Persistent Activation of NF-?B in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell. 2016 07 07; 19(1):52-65.
Score: 0.016
-
Sekhar KR, Benamar M, Venkateswaran A, Sasi S, Penthala NR, Crooks PA, Hann SR, Geng L, Balusu R, Abbas T, Freeman ML. Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1106-1114.
Score: 0.014
-
Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol. 2014 Aug 15; 737:140-8.
Score: 0.014
-
Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, Clair DK, Clair WH. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res. 2013 Jul 15; 73(14):4406-17.
Score: 0.013
-
Yip-Schneider MT, Wu H, Stantz K, Agaram N, Crooks PA, Schmidt CM. Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17; 13:194.
Score: 0.013
-
Yip-Schneider MT, Wu H, Hruban RH, Lowy AM, Crooks PA, Schmidt CM. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas. 2013 Jan; 42(1):160-7.
Score: 0.013
-
Adeneye Adejuwon A, Crooks PA, Fadhel-Albayati Z, Miller AF, Zito SW, Adeyemi OO, Agbaje EO. Antihyperglycemic profile of erinidine isolated from Hunteria umbellata seed. Afr J Tradit Complement Altern Med. 2013; 10(2):189-202.
Score: 0.013
-
Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg. 2012 Jul; 16(7):1333-40.
Score: 0.012
-
Estabrook NC, Chin-Sinex H, Borgmann AJ, Dhaemers RM, Shapiro RH, Gilley D, Huda N, Crooks P, Sweeney C, Mendonca MS. Inhibition of NF-?B and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radic Biol Med. 2011 Dec 15; 51(12):2249-58.
Score: 0.012
-
Sekhar KR, Reddy YT, Reddy PN, Crooks PA, Venkateswaran A, McDonald WH, Geng L, Sasi S, Van Der Waal RP, Roti JL, Salleng KJ, Rachakonda G, Freeman ML. The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. Clin Cancer Res. 2011 Oct 15; 17(20):6490-9.
Score: 0.012
-
Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ. A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-?B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10):2481-94.
Score: 0.011
-
Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, Jordan CT. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23; 116(26):5983-90.
Score: 0.011
-
Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Nakshatri H, Sweeney CJ. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species. Prostate. 2010 Jul 01; 70(10):1074-86.
Score: 0.011
-
Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007 Dec 15; 110(13):4427-35.
Score: 0.009
-
Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007 Jun; 6(6):1736-44.
Score: 0.009
-
Sekhar KR, Crooks PA, Sonar VN, Friedman DB, Chan JY, Meredith MJ, Starnes JH, Kelton KR, Summar SR, Sasi S, Freeman ML. NADPH oxidase activity is essential for Keap1/Nrf2-mediated induction of GCLC in response to 2-indol-3-yl-methylenequinuclidin-3-ols. Cancer Res. 2003 Sep 01; 63(17):5636-45.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|